Evidence map›Paper›PMID 40125242›Full record

ArticleCureus2025

Novel Management of Post-laparoscopic Sacrocolpopexy-Associated Overactive Bladder: A Combined Approach of Vaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) Mesh Removal and Fotona Laser Therapy.

Nobuo Okui, Machiko Okui

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Nobuo OkuiUrogynecology, Yokosuka Urogynecology and Urology Clinic, Yokosuka, JPN.
Machiko OkuiUrogynecology, Yokosuka Urogynecology and Urology Clinic, Yokosuka, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This case report presents a novel approach for managing overactive bladder (OAB) syndrome following laparoscopic sacrocolpopexy (LSC) using vaginal natural orifice transluminal endoscopic surgery (vNOTES) and Fotona laser therapy. A 73-year-old woman with severe OAB syndrome and pelvic pain after LSC underwent mesh removal via vNOTES. Despite the initial improvement in OAB symptoms, the patient continued to experience persistent urinary issues. Subsequent treatment with Fotona's non-ablative erbium:yttrium-aluminum-garnet (Er:YAG) laser therapy, including Vaginal Erbium Laser (VEL) and Urethral Erbium Laser (UEL), led to the complete resolution of OAB symptoms. The patient's Overactive Bladder Symptom Score (OABSS) significantly improved following combined vNOTES and laser therapy. Follow-up assessments revealed sustained improvements in bladder function and quality of life. This case highlights the potential of combining vNOTES for mesh removal and Fotona laser therapy for managing post-LSC complications, particularly in cases in which mesh-related issues contribute to persistent OAB syndrome. The successful outcome, as evidenced by symptom resolution and improved OABSS, suggests that this approach may offer a viable solution for patients experiencing persistent OAB syndrome following LSC, especially when conventional treatment fails. This report contributes to the limited body of evidence on managing LSC-related OAB syndrome and introduces a promising treatment protocol using Fotona laser therapy, which merits further investigation in larger studies focused on OAB management after pelvic floor surgery.

Indexed as

fotona laser therapylaparoscopic sacrocolpopexymesh complicationsnon-ablative erbium yag laseroveractive bladdervaginal natural orifice transluminal endoscopic surgery

Identifiers

PMID40125242
PMCPMC11926921

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.